Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

Abstract Background Sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of kidney and heart failure events independent of glycemic effects. We assessed whether initiation of the SGLT2 inhibitor canagliflozin guided by multivariable predicted risk based on clinical characteristics and...

Full description

Bibliographic Details
Main Authors: Sok Cin Tye, Niels Jongs, Steven G. Coca, Johan Sundström, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Priya Vart, Hiddo. J. L. Heerspink
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Cardiovascular Diabetology
Subjects:
Canagliflozin
Type 2 diabetes
Treatment strategy
Kidney disease
Heart failure
Online Access:https://doi.org/10.1186/s12933-022-01619-0

Internet

https://doi.org/10.1186/s12933-022-01619-0

Similar Items